WAEDENSWIL, Switzerland (BUSINESS WIRE) May 20, 2021
Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors. Concurrent with the financing, Nanna Lüneborg from Novo Ventures, Matthias Fehr from HBM Partners, and Carlo Incerti from Forbion have been appointed to Numabâs Board of Directors.
Investegate |RTW Venture Fund Ltd Announcements | RTW Venture Fund Ltd: New Investment in Numab Therapeutics investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Launch of Novel Gene Therapy Company, VectorY, to Develop Innovative Vectorized Antibodies
Targeting muscular and neurodegenerative disorders
Amsterdam-based company seeded by Forbion
Co-founded by highly experienced gene therapy technology and manufacturing team
VectorY, a fully integrated gene therapy company focused on the development of innovative vectorized antibodies for muscular and neurodegenerative disorders, today announces its official launch. The Company has been operational since October 2020 and has established its laboratories and offices at the Amsterdam Science Park in The Netherlands.
VectorY develops proprietary and partnered programs based on a novel AAV platform and innovative antibody-based targeted degradation technologies. The Company is creating a pipeline of innovative vectorized antibodies targeting muscular and CNS diseases, aimed at overcoming limitations of current therapies, specifically by improving delivery, durability and accessibility of targe